A first in-man phase I and IIa study (self-adjuvanted mRNA vaccination in advanced prostate cancer patients) was conducted in (2015) by Hubert Kubler and his team on 44 advanced prostate cancer patients at 12 centers in Germany and Italy, and the result was 91% were evaluable for (prostate-specific antigen) PSA response [22]. Here, KLK3 is linked to prostate carcinoma.